Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/23190
標題: IL-16在非小細胞肺癌之臨床意義
Clinical Significance of IL-16 in Non-Small Cell Lung Cancer
作者: 林宜嫻
Lin, Yi-Shyan
關鍵字: 介白質-16;IL-16;CD4受體;膜蛋白Fas;CD4 receptor;Fas
出版社: 生命科學院碩士在職專班
引用: Aarden L, Brunner T, Cerottini J, Dayer J, de Weck A,Dinorello C, et al:Revised nomenclature for antigen-nonspecific T cell proliferation and helper factors. J Immunol 1979;123:2928-9. Abbas AK, Lichtman AH, Pober JS:Cellular and Molecular Immunology, Updated Edition,5th edition 2004 Alberg AJ, Brock MV, Samet JM:Epidemiology of lung cancer: looking to the future. J Clin Oncol 2005;23:3175-85. Review. Arima M, Plitt J, Stellato C, Bickel C, Motojima S, Makino S, Fukuda T, Schleimer RP:Expression of interleukin-16 by human epithelial cells. Inhibition by dexamethasone.Am J Respir Cell Mol Biol 1999;21:684-92. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Storkel S: Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004;52:893-901. Baier, M., Werner, A., Bannert, N., Metzner, K., Kurth, R:HIV suppression by interleukin-16. Nature 1995;378:563. Baier, M., Bannert, N., Werner, A., Lang, K., Kurth, R:Molecular cloning, sequence,expression, and processing of the interleukin 16 precursor. Proc Natl Acad Sci USA 1997;94:5273–7. Bannert N, Avots A, Baier M, Serfling E, Kurth R:GA-binding protein factors, in concert with the coactivator CREB binding protein/p300, control the induction of the interleukin 16 promoter in T lymphocytes. Proc Natl Acad Sci USA 1999;96:1541-6. Bazan, J.F., Bacon, K.B., Hardiman, G., Wang, W., Soo, K., Rossi, D., Graves, D.R., Zlotnik, A., and Schall, T.J:A new class of membrane-bound chemokine with a CX3 C motif. Nature 1997;385:640-4. Berman, J. S., Beer, D. J., Cruikshank, W. W., Center, D. M:Chemoattractant lymphokines specific for the helper /inducer T-lymphocyte subset. Cell Immunol 1985;95:105-12. Bellini, A., Yoshimura, H., Vitori, E., Marini, M., Mattoli, S. J:Bronchial epithelial cells of patients with asthma release chemoattractant factors for T lymphocytes. J Allergy Clin Immunol 1993;92:412–24. Bloom B R & Bennett B:Mechanism of a reaction in vitro associated with delayed type hypersensitivity. Science 1996;153: 80-2. Carswell, E.A., Old, L.J., Kassel, R.L., Green, S., Fiore, N., Williamson, G:An endotoxin induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-70. Center, D. M., Cruikshank, W. W:Modulation of lymphocyte migration by human lymphokines. I. Identification and characterization of chemoattractant activity for lymphocytes from mitogen-stimulated monuclear cells. J Immunol 1982;128:2563–8. Center, D. M., Kornfeld, H., Cruikshank, W. W:Interleukin -16 and its functions as a CD4 ligand. Immunol Today 1996;17:476–81. Center DM, Kornfeld H, Ryan TC, Cruikshank WW:Interleukin 16:implications for CD4 functions and HIV-1 progression. Immunol Today 2000;21: 273-80. Review. Center DM, Cruikshank WW, Zhang Y:Nuclear pro-IL-16 regulation of T cell proliferation: p27(KIP1)-dependent G0/G1 arrest mediated by inhibition of Skp2 transcription.J Immunol 2004;172:1654-60. Cocchi, F.; DeVico, AL; Garzino-Demo, A.; Arya, SK; Gallo, RC; Lusso, P: Identification of RANTES, MIP-1a and MIP-1βas the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-5. Cohen S, Ward P, Bigazzi P:Cell cooperation in cell mediated immunity. In: McCluskey R, Cohen S, eds:Mechanisms of cell-mediated immunity. New York:Wiley,1974:331-8. Cruikshank, W.W., Center, D. M:Modulation of lymphocyte migration by human lymphokines. II. Purification of lymphotactic factor (LCF). J Immunol 1982;128:2569–71. Cruikshank, W. W., Berman, J. S., Theodore, A. C., Bernardo, J., Center,D. M:Lymphokine activation of T4+lymphocytes and moncytes. J Immunol 1987;138:3817-23. Cruikshank, W. W., Center, D. M., Nisar, N., Natke, B., Theodore, A. C.,Kornfeld, H:Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression. Proc Natl Acad Sci USA 1994;91:5109–13. Cruikshank, W. W., Theodore, A. C., Fine, G., Lim, K. G., Weller, P. F.,Center, D. M:Suppression of anti-CD3 stimulated T cell proliferation by IL-16. J Immunol 1996;157:5240-8. Cruikshank,W.W., Kornfeld, H., Berman, J., Chupp, G., Keane, J., Center,D: Biologic activities of interleukin 16. Nature 1996;382:501–2. Chupp GL, Wright EA, Wu D, Vallen-Mashikian M, Cruikshank WW, Center DM, Kornfeld H, Berman JS:Tissue and T cell distribution of precursor and mature IL-16. J Immunol 1998;161:3114-9. David JR:Delayed hypersensitivity in vitro: Its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci 1966;56:72-7. Deng, H., Liu,R., Ellmeier,W., Choe,S.,Unutmaz, D., Burkhart,M., Di Marzio P.,Marmon,S., Sutton, R.E.,Hill, G.M., Davis, C.B., Peiper, S.C.,Schall, T.J., Littman, D.R., and Landau,N. R:Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-7. Dumonde D,Wolstencroft R,Panayi G,Matthew M,Morley J,Howson W: Lymphokines: non-antibody mediators of cellular immunity generated by lymphocyte activation〔letter〕.Nature 1969;224:38-42. Fearon, D.T., Locksley, R.M:Instructive role of innate immunity in the acquired immune response. Science 1996;272:50–4. Franz, J. K., Kolb, S. A., Hummel, K. M., Lahrtz, F., Neidhart, M., Aicher,W. K., Pap, T., Gay, R. E., Fontana, A., Gay, S:Interleukin-16,produced by synovial fibroblasts, mediates chemoattraction for CD4+ T lymphocytes in rheumatoid arthritis. Eur J Immunol 1998;28:2661–71. Gresser, I., Nacify, K:Recovery of an interferon-like substance from cerebrospinal fluid. Proc Soc Exp Biol Med 1964;117: 285–9. Idziorek, T., Billaut-Mulot, O., Hermann, E., Aumercier, M., Mouton, Y.,Capron, A., Bahr, G. M:Recombinant human IL-16 inhibits HIV-1 replication and protects against activation-induced cell death (AICD). Clin Exp Immunol 1998;112:84–91. International Committee:Interferons nomenclature.Nature 1980;286:110. Isaacs, A., Lindenmann, J:"Virus interference I: The interferon". Proc Roy Soc London Series B Biological Sciences 1957;147;258-267. Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S., Sameshima, M.,Hase, A., Seto, Y., and Nagata, S:The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-43. Kaser, A., Dunzendorfer, S., Offner, F. A., Ryan, T., Schwabegger, A.,Cruikshank, W. W., Wiedermann, C. J., Tilg, H:A role for IL-16 in the cross-talk between dendritic cells and T cells. J Immunol 1999;163:3232–8. Keates, A. C., Cruikshank, W.W., I. Castagliuolo, B. S. Qiu, K. O’Dell, C. P. Kelly:Anti-IL-16 mAb therapy protects against TNBS-colitis in mice. Gastroenterology 1997;112:A110. Keane J, Nicoll J, Kim S, Wu DM, Cruikshank WW, Brazer W, Natke B, Zhang Y, Center DM, Kornfeld H:Conservation of structure and function between human and murine IL-16.J Immunol 1998;160:5945-54. Kim, H. S:Assignment of human interleukin 16 (IL16) to chromosome 15q26.3 by radiation hybrid mapping. Cytogenet Cell Genet 1999;84:93. Kreuzer M, Heinrich J, Kreienbrock L, Rosario AS, Gerken M, Wichmann HE:Risk factors for lung cancer among nonsmoking women. Int J Cancer 2002;100:706-13. Kuna P, Reddigari SR, Schall TJ, Rucinski D, Viksman MY,Kaplan AP:RANTES, a monocyte and T lymphocyte chemotactic cytokine releases histamine from human basophils. J Immunol 1992;149:636. Laberge, S., Cruikshank, W. W., Kornfeld, H., Center, D. M:Histamine-induced secretion of lymphocyte chemoattractant factor from CD8+T cells is independent of transcription and translation: Evidence for constitutive protein synthesis and storage. J Immunol 1995;55:2902–10. Laberge, S., Cruikshank, W. W., Kornfeld, H., Beer, D. J., Center, D. M:Secretion of IL-16 (lymphocyte chemoattractant factor) from serotonin-stimulated CD8+T cells in vitro.J Immunol 1996;156:310–5. Laberge, S., Ernst, P., Ghaffar, O., Cruikshank,W.W., Kornfeld, H., Center,D. M., Hamid, Q:Increased expression of IL-16 in bronchial mucosa of subjects with atopic asthma. Am J Respir Cell Mol Biol 1997;17:193–202. Lai, K. N., Ho, S., Leung, J. C. K., and Tsao, S. Y:Soluble interleukin-2 receptors in patients with nasopharyngeal carcinoma. Cancer(Phila.) 1991;67:2180–5. Lee, M. E., Adams, J. W., Villinger, F., Brar, S. S., Meadows, M., Bucur,S. Z., Lackey, D. A., Brice, G. T., Cruikshank,W.W., Ansari, A. A., Hillyer,C. D: Molecular cloning and expression of Rhesus Macaque and Sooty Mangabey interleukin 16: biologic activity and effect on simian immunodeficiency virus infection and/or replication.AIDS Res Hum Retrovirus 1998;14:1323–8. Lee, S., H. Kaneko, I. Sekigawa, Y. Tokano, Y. Takasaki, H. Hashimoto:Circulating interleukin-16 in systemic lupus erythematosus. Br J Rheumatol 1998;37:1334. Levy, J. A., Mackewicz,C.E., and Barker,E:Controlling HIV pathogenesis:the role of the noncytotoxic anti-HIV response of CD8+ T cells. Immunol Today 1996;17:21. Lim KG, Wan HC, Bozza PT, Resnick MB, Wong DT, Cruikshank WW, Kornfeld H, Center DM, Weller PF:Human eosinophils elaborate the lymphocyte chemoattractants IL-16 (lymphocyte chemoattractant factor) and RANTES. J Immunol 1996;156:2566–70. Li S, Satoh T, Korngold R, Huang Z:CD4 dimerization and oligomerization: implications for T-cell function and structure-based drug design. Immunol Today 1998;19:455-62. Liu, Y., Cruikshank, W. W., O’Loughlin, T., O’Reilly, P., Center, D. M.,Kornfeld, H:Identification of a CD4 domain required for IL-16 binding and lymphocyte activation. J Biol Chem 1999;274:23387–95. Maciaszek, J. W., Parada, N. A., Cruikshank, W. W., Center, D. M.,Kornfeld, H., Viglianti, G. A:Interleukin-16 represses HIV-1 promoter activity. J Immunol 1997;158:5–8. Maghazachi AA, Al-Aoukaty A, Schall TJ:CC chemokines induce the generation of killer cells from CD56/ cells.Eur J Immunol 1996;26:315. Massague, J:The TGF 1 family of growth and differentiation factors. Cell 1987;49:437–8. Mathy N.L.; Scheuer W.; Lanzendörfer M.; Honold K.; Ambrosius D.; Norley S.; Kurth R:Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes . Immunology 2000;100:63-9. Miller, M.D. and Krangel, M.S:Biology and biochemistry of the chemokines:a family of chemotactic and inflammatory cytokines. Crit Rev Immunol 1992;12:17-46. Murakami, S., Satomi, A., Ishida, K., Murai, H., and Okamura, Y:Serum soluble interleukin-2 receptor in colorectal cancer. Acta Oncol 1994;33:19–21. Morris A, Zvetkova I:Cytokine research: the interferon paradigm. J Clin Pathol 1997;50:635–9. Muhlhahn, P., Zweckstetter, M., Georgescu, J., Ciosto, C., Renner, C.,Lanzendorfer, M., Lang, K., Ambrosius, D., Baier, M., Kurth, R., Holak,T. A:Structure of interleukin 16 resembles a PDZ domain with an occluded peptide binding site. Nature Struct Biol 1998;5:682–6. Nelson BH, Willerford DM:Biology of the interleukin-2 receptor. Adv Immunol 1998;70:1-81. Review. Nicoll, J., Cruikshank, W. W., Brazer, W., Liu, Y., Center, D. M., Kornfeld,H:Identification of domains in IL-16 critical for biologic activity. J Immunol 1999;163:1827–32. Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K:Properties of the novel proinflammatory supergene ‘‘intercrine’’family. Annu Rev Immunol 1991;9:617. Ortegel JW, Staren ED, Faber LP, Warren WH, Braun DP:Cytokine biosynthesis by tumor-infiltrating T lymphocytes from human non-small-cell lung carcinoma.Cancer Immunol Immunother 2000;48:627-34. Osoegawa A, Yoshino I, Tanaka S, Sugio K, Kameyama T, Yamaguchi M, Maehara Y:Regulation of p27 by S-phase kinase-associated protein 2 is associated with aggressiveness in non-small-cell lung cancer. J Clin Oncol 2004;22:4165-73. Parada, N. A., Ryan, T. C., Danis, H., Cruikshank, W. W., Center, D. M:IL-16 and other CD4 ligand-induced migration is dependent upon protein kinase C. Cell Immunol 1996;168:100–6. Parada, N. A., Cruikshank, W. W., Kornfeld, H., Center, D. M:Synergistic activation of CD4+T cells by interleukin 16 and interleukin 2. J Immunol 1998;160:2115–20. Rand, T., Cruikshank, W. W., Center, D. M., Weller, P. F:CD4-mediated stimulation of human eosinophils: lymphocyte chemoattractant factor and other CD4-binding ligands elicit eosinophil migration. J Exp Med 1991;173:1521–8. Ruddle, N. H., Waksman,B.H:Cytotoxic effect of lymphocyte-antigen interaction in delayed hypersensitivity. Science 1967;157:1060 Rumsaeng, V., Cruikshank, W. W., Foster, B., Prussin, C., Kirshenbaum,A. S., Davis, T. A., Kornfeld, H., Center, D. M., Metcalf, D. D:Human mast cells produce the CD41 T lymphocyte chemoattractant factor,Interleukin 16. J Immunol 1997;159:2904–10. Schall TJ, Jongstra J, Dyer BJ, Jorgensen J, Clayberger C,Davis MM, Krensky AM:A human T cell-specific molecule is a member of a new gene family. J Immunol 1988;141:1018. Schluesener, H. J., Seid K., Kretzschmar J., Meyermann R:Leukocyte chemotactic factor, a natural ligand to CD4, is expressed by lymphocytes and microglial cells of the MS plaque. J Neurosci Res 1996;44:606. Shalaby MR, Aggarwal BB, Rinderknecht E, Svedersky LP, Finkle BS, Palladino MA Jr:Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. Immunol 1985;135:2069. Sherry B, Tekamp-Olson P, Gallegos C, Bauer D, Davatelis G, Wolpe SD, Masiarz F, Coit D, Cerami A:Resolution of the two components of macrophage inflammatory protein 1, and cloning and characterization of one of those components, macrophage inflammatory protein 1b. J Exp Med 1988;168:2251. Shimada, M., Matsumata T., Taketomi A., Shirabe K., Yamamoto K., Takenaka K., Sugimachi K:The role of interleukin-6, interleukin-16, tumor necrosis factor-alpha and endotoxin in hepatic resection. Hepatogastroenterology 1995;42:691. Smith, K.A:Interleukin-2: inception,impact and implications. Science 1988;240:1169–76. Stewart WE, Blalock JE, Burke DC, Chany C, Dunnick JK, Falcoff E, Friedman RM, Galasso GJ, Joklik WK, Vilcek JT, Youngner JS, and Zoon KC:Interferon nomenclature. Nature 1980;286:110. Stoitzner P, Ratzinger G, Koch F, Janke K, Scholler T, Kaser A, Tilg H, Cruikshank WW, Fritsch P, Romani N:Interleukin-16 supports the migration of Langerhans cells, partly in a CD4-independent way. J Invest Dermatol 2001;116:641-9. Theodore, A.C., Center, D.M., Nicoll, J., Fine,G., Kornfeld, H.,Cruikshank, W.W:The CD4 ligand interleukin 16 inhibits the mixed lymphocyte reaction. J Immunol 1996;157:1958–64. Walz A, Peveri P, Aschauer H, Baggiolini M:Purification and amino acid sequencing of NAF, a novel neutrophil activating factor produced by monocytes. Biochem Biophys Res Commun 1987;149:755. Wang LS, Chow KC, Li WY, Liu CC, Wu YC, Huang MH:Clinical significance of serum soluble interleukin 2 receptor-alpha in esophageal squamous cell carcinoma.Clin Cancer Res 2000;6:1445-51. Ward, P.A., Remold, H.G., David, J.R:The production by antigen-stimulated lymphocytes of a leukotactic factor distinct from migration inhibitory factor. Cell Immunol 1970;1:162–74 . Wheelock, E.F:Interferon-like virus inhibitor induced in human leukocytes by phytohemagglutinin. Science 1965;141:310–11. Wilhelm S, Wagner H, Hacker G:Activation of caspase-3-like enzymes in non-apoptotic T cells. Eur J Immunol 1998;28:891-900. Woods, D., Bryant, P:ZO-1, DIgA and PSD-95/SAP90: homologous proteins in tight, septate and synaptic cell junctions. Mech Dev 1995;44:85–9. Wu, D. M. H., Zhang, Y., Parada, N. A., Kornfeld, H., Nicoll,J., Center,D. M., Cruikshank, W. W:Processing and release of interleukin-16 from CD41 but not CD81 T cells is activation dependent. J Immunol 1999;162:1699. Yoshimura T, Matsushima K, Tanaka S, Robinson EA, Appella E, Oppenheim JJ, Leonard EJ:Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA 1987;84:9233–7. Youngner, J., Salvin, S.B:Production and properties of migration inhibitory factor and interferon in the circulation of mice with delayed type hypersensitivity. J Immunol 1973;111:1914–22 . Zhang, Y., Center, D. M., Cruikshank, W. W., Kornfeld, H:Processing and activation of interleukin 16 by caspase 3. J Biol Chem 1998;273:1144. Zhang Y, Kornfeld H, Cruikshank WW, Kim S, Reardon CC, Center DM:Nuclear translocation of the N-terminal prodomain of interleukin-16. J Biol Chem 2001;276:276:1299-303. Zhou, P., Devadas, K., Tewari, D., Jegorow, A., Notkins, A. L:Processing, secretion, and anti-HIV-1 activity of IL-16 with or without a signal peptide in CD41 T cells. J Immunol 1999;163:906–12. 肺癌診治共識 國家衛生研究院 癌症研究組 臺灣癌症臨床研究合作組織 印行 中華民國八十七年八月出版
摘要: 
IL-16是第一個被證實對人類T淋巴細胞具有趨化活性特徵的細胞激素,因此被稱為淋巴細胞化學趨化因子(lymphocyte chemoattractant factor,LCF)。因其結構上第22個胺基酸位置含有單一個半胱胺酸殘基而被歸屬於C化學趨化激素(C-chemokines)的家族成員之一。IL-16作用在表現CD4受體的細胞,不但可趨化標的細胞聚集至發炎部位,也能調節參與先天性免疫的單核球及應變性免疫的樹突細胞及T淋巴細胞,形成發炎及免疫反應之間的橋樑,近年來更被學者發現可抑制HIV-1的複製,此外,IL-16也會向上調節細胞表現IL-2受體,亦可向下調節Fas的表現,也與細胞週期G0/G1的調控有關,這些機制都和細胞增殖以及免疫監控之逃避有關,腫瘤細胞是否以上述各種不同作用逃避宿主之免疫監控,目前所知有限;並且到目前為止,腫瘤細胞是否表現IL-16、表現程度如何,尚未有文獻發表過,有待更進一步的探討。
本論文以原位雜交法、免疫組織染色法及反轉錄聚合酶連鎖反應偵測非小細胞肺癌細胞中IL-16的表現,發現七成以上的肺癌檢體,IL-16都有過量的表現,進一步分析病人存活曲線也發現,IL-16的表現量愈高,存活期愈短。因此,IL-16表現量的高低或許可以成為一個新的臨床肺癌腫瘤指標。

Interleukine-16 (IL-16) is the first identified as a chemoattractant characterized for human T lymphocytes; and IL-16 was therefore named as lymphocyte chemoattractant factor (LCF). Based on a single cysteine identified at the position of 22nd amino acid, IL-16 was recognized as a member of C-chemokine family. In general, IL-16 reacts with cells that express CD4 receptor. Owing to its chemoattractant feature,IL-16 not only can accumulate target cells in the inflammatory site, but also mediate monocyte-related innate immunity. IL-16 also plays a role in activating dendritic cells and T lymphocytes that are essential for acquired immunity as well as inflammation and immune responses. Recently, IL-16 was further shown to repress HIV-1 replication. In addition, IL-16 could up-regulate expression of interleukine-2 receptor , down-regulate expression of Fas and induce cell cycle progression from G0 to G1, the mechanisms that are closely associated with tumor cell proliferation and the escape of immune surveillance. Nonetheless, whether tumor cells took advantage of these characteristics to avoid host immune control are yet to be determined, and they are worthy for more detailed investigation.
In this study, we investigated the expression of IL-16 in non-small cell lung cancer (NSCLC) by using in situ hybridization, immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR). Our results showed that IL-16 was overexpressed in more than 70% of lung cancer cells. Survival analysis further demonstrated that patients with higher level of IL-16 expression had the worse prognosis. Therefore, our data suggested that the level of IL-16 in lung cancer cells might be a new tumor marker for NSCLC.
URI: http://hdl.handle.net/11455/23190
其他識別: U0005-0308200619132000
Appears in Collections:生命科學系所

Show full item record
 

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.